trending Market Intelligence /marketintelligence/en/news-insights/trending/WDkrR-YraczLy3BKsJ32yQ2 content esgSubNav
In This List

HTG Molecular Diagnostics completes $19M stock offering, $3.5M placement

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


HTG Molecular Diagnostics completes $19M stock offering, $3.5M placement

HTG Molecular Diagnostics Inc. completed an offering of common shares and a private placement of prefunded warrants for aggregate gross proceeds of $22.5 million.

The company sold 29,298,537 common shares priced at 65 cents apiece under the public offering, as well as 3,821,548 shares sold after the underwriters exercised their option in full to purchase additional shares. Total gross proceeds from the public offering was about $19 million.

Meanwhile, the company sold 5,411,687 prefunded warrants exercisable for a total of 5,411,687 common shares at 64 cents each under a concurrent private placement. The placement raised about $3.5 million in gross proceeds.

Cantor Fitzgerald & Co. acted as sole book-running manager for the public offer.

Tucson, Ariz.-based HTG provides technology to help develop precision medicine and identify treatment options for patients.